Amgen Will Not Pursue Sensipar Indication In Chronic Renal Insufficiency Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III study of secondary hyperparathyroidism drug in patients with chronic renal insufficiency demonstrated incidences of hypocalcemia.
You may also be interested in...
Sensipar Label Has Precautions On Hypocalcemia; Pre-Dialysis Indication Could Be Challenge
Amgen's chronic kidney disease treatment Sensipar includes precautions on hypocalcemia
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.